2023 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ : 2023-04-15
±³À°ÀÏÀÚ : 2023-04-15
±³À°Àå¼Ò : ¹é¹ü±è±¸±â³ä°ü
±³À°ÁÖÁ¦ : 2023 ´ëÇÑÄ¡¸ÅÇÐȸ Ãá°è Çмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÄ¡¸ÅÇÐȸ
´ã´çÀÚ : ±èÁÖ¿Á
¿¬¶ôó : 02-587-7462
À̸ÞÀÏ : secretkda@thedementia.co.kr
±³À°Á¾·ù : ½Å°æ°ú
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 10 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 110,000¿ø
ºñ°í »çÀüµî·Ï: ÀϹÝȸ¿ø 3¸¸¿ø, Á¤È¸¿ø 5¸¸¿ø, ºñȸ¿ø 10¸¸¿ø / ´çÀϵî·Ï: ÀϹÝȸ¿ø 4¸¸¿ø, Á¤È¸¿ø 6¸¸¿ø, ºñȸ¿ø 11¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 04-15 08:50~09:00 Opening Remarks ´ëÇÑÄ¡¸ÅÇÐȸÀå()
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room A) 09:00~09:20 ÁÖÁ¦: Gantenerumab Tobias Bittner(Roche Diagnostics)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room A) 09:20~09:40 ÁÖÁ¦: Lecanemab Michael Irizarry(Eisai Inc)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room A) 09:40~10:00 ÁÖÁ¦: Donanemab Stephane Epelbaum(Lilly International)
ÈÞ½Ä 04-15 ¹é¹ü±è±¸±â³ä°ü 10:00~10:20 Coffee Break ()
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room A) 10:20~11:20 Çѱ¹ ½Å°æ ½É¸®»çÀÇ ¹ßÀü»ç ¹× Ä¡¸ÅÀÇ Áø´Ü°ú Ä¡·á¿¡ ´ëÇÑ Àû¿ë °¿¬¿í(ÇѸ²´ë ½É¸®Çаú)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room A) 11:20~12:20 A clinicogenetic spectrum among personality trait, psychiatric disease and FTD Yolande Pijnenburg(Amsterdam University Medical Center, Netherlands)
½Ä»ç 04-15 ¹é¹ü±è±¸±â³ä°ü (Room A) 12:20~13:00 ÃÑȸ ¹× Lunch ()
Åä·Ð 04-15 ¹é¹ü±è±¸±â³ä°ü 13:00~14:00 Poster Presentation ()
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room A) 14:00~15:00 ±¸¿¬ (ÁÖÁ¦: Basic Science and Pathogenesis / Biomarkers / Clinical Manifestations / Neuropsychological assessment) ´Ù°»ç(´Ù¼Ò¼Ó)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room B) 14:00~15:00 ±¸¿¬ (ÁÖÁ¦: Dementia Care / Pharmacological & Non-pharmacological treatment / Risk factors, Public health and Epidemiology) ´Ù°»ç(´Ù¼Ò¼Ó)
ÈÞ½Ä 04-15 ¹é¹ü±è±¸±â³ä°ü 15:00~15:10 Coffee Break ()
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room A) 15:10~15:40 C9orf72: probably ethnic difference? ±è¿µÀº(ÇѾçÀÇ´ë)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room A) 15:40~16:10 C9orf72: probably missed? ¹®¼Ò¿µ(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room B) 15:10~15:30 Preventive and therapeutic effects of Korean red ginseng polysaccharides on Alzheimer¡¯s disease ¹®¹ÎÈ£(°Ç¾ç´ë)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room B) 15:30~15:50 Alzheimer's Disease and Synaptic plasticity; A New Protection Strategy Á¶ÁöÈÆ(Àü³²´ë)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room B) 15:50~16:10 Targeting P.gingivalis as a new AD protection strategy ±èÀ±°æ(KIST ³ú°úÇבּ¸¼Ò)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room A) 16:10~16:30 Neural correlates of BPSD ÀÓÀ缺(¿ï»êÀÇ´ë)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room A) 16:30~16:50 Pharamacological management of BPSD ÀÌÂù³ç(°í·ÁÀÇ´ë)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room A) 16:50~17:10 Non-pharamacological management of BPSD ¼ÛÁؾÆ(°í·Á´ë °£È£Çаú)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room B) 16:10~16:40 Ä¡¸Å ȯÀÚ¿Í ¿¬°üµÈ À±¸®Àû ¹®Á¦ ³ªÇظ®(º¸¹Ù½º±â³äº´¿ø)
±³À°½Ã°£ 04-15 ¹é¹ü±è±¸±â³ä°ü (Room B) 16:40~17:10 Ä¡¸Å ȯÀÚ¿Í ¿¬°üµÈ ¹ýÀû ºÐÀï »ç·Ê ÇÔö¼º(¼ÁØ ¹ý·ü»ç¹«¼Ò)
±âŸ 04-15 ¹é¹ü±è±¸±â³ä°ü 17:10~17:30 Closing Remarks ¹× ½Ã»ó½Ä ()